{"id":37007,"date":"2021-11-17T18:13:56","date_gmt":"2021-11-17T18:13:56","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=37007"},"modified":"2021-11-17T18:20:52","modified_gmt":"2021-11-17T18:20:52","slug":"david-wyatt","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/","title":{"rendered":"David Wyatt"},"content":{"rendered":"
\n\n\t

David Wyatt<\/h2>\n

Chief Operating Officer at Aston Particle Technologies<\/h4>\n\t

David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing. During that time, he and his teams assisted in the development of 5 respiratory medicines from molecule selection to be amongst today’s gold standard treatments for asthma and chronic obstructive pulmonary disease.<\/p>\n

His cv lists Evohaler\u2122 pressurised Metered Dose Inhalers, Diskus\u2122 and Ellipta\u2122 Dry Powder Inhalers as well as intranasal and antiviral respiratory medicines. In his final position at GSK, which he held for 8 years, he was responsible for the technical aspects of respiratory new product introduction. His supply chain experience enhances his appreciation of the importance of maintaining product knowledge and hands-on experience in the provision of life-saving medicines.<\/p>\n

He is now the Chief Operating Officer at Aston Particle Technologies Ltd a spin-out SME with a revolutionary new dispersion technology and he is an Honorary Professor of Pharmaceutical Sciences at Aston University. He is a past chair and board member of the Academy of Pharmaceutical Sciences UK.<\/p>\n\t\t\t\t\t\t\t\"David\t\t\t\t\t\t\t\n

\n\tTitle: The development and supply of respiratory medicines\n\t<\/h3>\n

\n\t\t\t\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t

Aston Particle Technologies<\/a><\/p>\n

\n\t\t\t\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t

Visit profile<\/a><\/p>\n\n<\/div>","protected":false},"excerpt":{"rendered":"

David Wyatt Chief Operating Officer at Aston Particle Technologies David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing. During that time,…<\/p>\n","protected":false},"author":1,"featured_media":37008,"parent":15585,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-37007","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nDavid Wyatt • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"David Wyatt • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-17T18:20:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/\",\"name\":\"David Wyatt • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg\",\"datePublished\":\"2021-11-17T18:13:56+00:00\",\"dateModified\":\"2021-11-17T18:20:52+00:00\",\"description\":\"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhalation & Respiratory Drug Delivery 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"David Wyatt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"David Wyatt • BioTech Pharma Summit","description":"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/","og_locale":"en_US","og_type":"article","og_title":"David Wyatt • BioTech Pharma Summit","og_description":"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-11-17T18:20:52+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/","name":"David Wyatt • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg","datePublished":"2021-11-17T18:13:56+00:00","dateModified":"2021-11-17T18:20:52+00:00","description":"David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/11\/David-Wyatt-Nov-2021_Biotech_Pharma_Summit_Profile.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/david-wyatt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Inhalation & Respiratory Drug Delivery 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/"},{"@type":"ListItem","position":3,"name":"David Wyatt"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/37007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=37007"}],"version-history":[{"count":3,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/37007\/revisions"}],"predecessor-version":[{"id":37014,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/37007\/revisions\/37014"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15585"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/37008"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=37007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}